Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.56%62.631.0%$426.63m
AMGNAmgen, Inc. -1.61%237.601.3%$415.39m
BIIBBiogen, Inc. 0.59%287.191.4%$362.99m
ILMNIllumina, Inc. 1.11%328.333.5%$323.56m
VRTXVertex Pharmaceuticals, Inc. -0.78%233.991.9%$273.36m
REGNRegeneron Pharmaceuticals, Inc. -5.76%363.712.6%$217.27m
EXASEXACT Sciences Corp. -2.45%85.9024.0%$197.11m
ITCIIntra-Cellular Therapies, Inc. -3.12%25.439.0%$173.46m
ALXNAlexion Pharmaceuticals, Inc. -0.23%113.012.0%$173.06m
INCYIncyte Corp. -2.30%78.652.5%$135.12m
SRPTSarepta Therapeutics, Inc. -3.84%122.9914.6%$133.04m
AAgilent Technologies, Inc. -0.56%89.621.6%$120.06m
BMRNBioMarin Pharmaceutical, Inc. -0.82%87.554.3%$106.16m
BLUEbluebird bio, Inc. -2.26%95.8214.2%$95.27m
SGENSeattle Genetics, Inc. -0.30%108.676.1%$90.33m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.